Variability of Intestinal Expression of P-Glycoprotein in Healthy Volunteers as Described by Absorption of Talinolol from Four Bioequivalent Tablets
- 1 March 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 92 (3), 604-610
- https://doi.org/10.1002/jps.10327
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestineEuropean Journal of Pharmaceutical Sciences, 2000
- Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interactionClinical Pharmacology & Therapeutics, 2000
- Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoproteinClinical Pharmacology & Therapeutics, 2000
- P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humansInt. Journal of Clinical Pharmacology and Therapeutics, 2000
- Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil*Clinical Pharmacology & Therapeutics, 1999
- Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans*Clinical Pharmacology & Therapeutics, 1996
- Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enantiomers: Concentration- and Dose-dependent Absorption in Vitro and in VivoPharmaceutical Research, 1996
- Metrics to Characterize Concentration-Time Profiles in Single- and Multiple-Dose Bioequivalence StudiesDrug Information Journal, 1995
- Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in manBiopharmaceutics & Drug Disposition, 1995
- International Harmonization of Regulatory Bioequivalence RequirementsClinical Research and Regulatory Affairs, 1993